What is Brainomix?
Founded in 2010 as a spinout from the University of Oxford, Brainomix specializes in the development of AI-driven diagnostic tools that transform standard medical imaging into actionable clinical intelligence. Its flagship e-Stroke platform serves as a critical decision-support system, enabling clinicians to interpret complex imaging data with unprecedented speed and accuracy. By bridging the gap between academic research and commercial healthcare application, the company addresses the urgent need for rapid, data-informed treatment protocols in acute stroke care. The firm's market position is defined by its deep integration into hospital workflows and its commitment to redefining global standards for neurological intervention through scalable, software-as-a-medical-device (SaMD) technology.
How much funding has Brainomix raised?
Brainomix has raised a total of $52.5M across 5 funding rounds:
Angel/Seed
$1.9M
Series A
$1.6M
Other Financing Round
$9.8M
Series B
$21.2M
Series C
$18M
Angel/Seed (2014): $1.9M with participation from Parkwalk Advisors Limited
Series A (2014): $1.6M led by University of Oxford Isis Fund and Chimera Partners
Other Financing Round (2018): $9.8M supported by Boehringer Ingelheim, Parkwalk Advisors, Oxford University Innovation Fund, and Chimera Partners
Series B (2021): $21.2M featuring Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Oxford University Innovation Fund, and Tencent
Series C (2025): $18M backed by Hostplus, Boehringer Ingelheim Venture Fund, and Parkwalk Advisors
Key Investors in Brainomix
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients, focusing on first-in-class, disease-modifying therapeutics.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities and bridging the gap between academic research and commercial success.
Tencent
Tencent is a global technology company that develops digital platforms and invests in technology innovation, supporting developers through a broad ecosystem of products and services.
What's next for Brainomix?
With the successful closure of this latest financing round, Brainomix is well-positioned to accelerate its international expansion and broaden its diagnostic portfolio. The strategic capital will likely be deployed to enhance the e-Stroke platform's capabilities, potentially integrating new modalities and expanding into adjacent therapeutic areas where rapid imaging analysis is paramount. As the company transitions from a scaling venture to a more mature enterprise-level player, the focus will shift toward deepening its footprint in key global markets, including the United States and Asia. Continued collaboration with its established investor base—which includes major pharmaceutical entities and specialized deeptech backers—will be instrumental in navigating regulatory landscapes and driving the widespread adoption of its life-saving AI technologies.
See full Brainomix company page
